1. A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis
- Author
-
Ki Eun Maeng, Lauren Greenberg, Madhusudana N. Shampur, Jun-Young Lee, Richard Franka, Cheol Min Kim, Modupe O. V. Osinubi, Sun Ju Keum, Soo Young Lee, Ji Min Seo, Hyunjoo Lee, Jung Sun Ahn, Kye Sook Yi, Minsoo Kim, Ji-Young Shin, Pan Kyeom Kim, Min Joo Choo, and Charles E. Rupprecht
- Subjects
RNA viruses ,Viral Diseases ,B Cells ,Physiology ,medicine.disease_cause ,Antibodies, Viral ,Pathology and Laboratory Medicine ,Biochemistry ,Mice ,White Blood Cells ,Medical Conditions ,Phage Display ,Animal Cells ,Immune Physiology ,Zoonoses ,Medicine and Health Sciences ,Enzyme-Linked Immunoassays ,Antigens, Viral ,Mammals ,Multidisciplinary ,Immune System Proteins ,biology ,Antibodies, Monoclonal ,Eukaryota ,Vaccination ,Molecular Biology Display Techniques ,Drug Combinations ,Infectious Diseases ,Medical Microbiology ,Viral Pathogens ,Viruses ,Vertebrates ,Medicine ,Antibody ,Pathogens ,Cellular Types ,Post-Exposure Prophylaxis ,Research Article ,Neglected Tropical Diseases ,medicine.drug_class ,Rabies ,Science ,Immune Cells ,Immunology ,India ,Monoclonal antibody ,Research and Analysis Methods ,Microbiology ,Virus ,Antibodies ,Rabies Virus ,Dogs ,Antigen ,Peptide Library ,medicine ,Animals ,Humans ,Molecular Biology Techniques ,Immunoassays ,Antibody-Producing Cells ,Lyssavirus ,Microbial Pathogens ,Molecular Biology ,Molecular Biology Assays and Analysis Techniques ,Blood Cells ,Mesocricetus ,Biology and life sciences ,business.industry ,Rabies virus ,Organisms ,Proteins ,Cell Biology ,medicine.disease ,biology.organism_classification ,Tropical Diseases ,Virology ,Antibodies, Neutralizing ,Disease Models, Animal ,Amniotes ,biology.protein ,Immunologic Techniques ,business ,Zoology ,Epitope Mapping ,Cloning - Abstract
Post-exposure prophylaxis (PEP) is highly effective in preventing disease progression of rabies when used in timely and appropriate manner. The key treatment for PEP is infiltration of rabies immune globulin (RIG) into lesion site after bite exposure, besides wound care and vaccination. Unfortunately, however, RIG is expensive and its supply is limited. Currently, several anti-rabies virus monoclonal antibody (mAb) products are under development as alternatives to RIG, and two recently received regulatory approval in India. In this study, fully human mAbs that recognize different rabies virus glycoprotein conformational antigenic site (II and III) were created from peripheral blood mononuclear cells of heathy vaccinated subjects. These mAbs neutralized a diverse range of lyssavirus types. As at least two anti-rabies virus mAbs are recommended for use in human PEP to ensure broad coverage against diverse lyssaviruses and to minimize possible escape variants, two most potent mAbs, NP-19-9 and 11B6, were selected to be used as cocktail treatment. These two mAbs were broadly reactive to different types of lyssaviruses isolates, and were shown to have no interference with each other. These results suggest that NP-19-9 and 11B6 are potent candidates to be used for PEP, suggesting further studies involving clinical studies in human.
- Published
- 2021